MyFinsight
Home
Blog
About
Contact
Download
Download image
Sales and maturities
of marketable...
$551,670K
Net proceeds from
issuance of common stock
$128,175K
Issuance of shares
through employee stock...
$2,589K
Proceeds from options
exercised
$722K
Net cash provided by
(used in) investing...
$228,031K
Net cash provided by
financing activities
$131,486K
Canceled cashflow
$323,639K
Net (decrease)
increase in cash, cash...
-$35,219K
Canceled cashflow
$359,517K
Stock-based compensation
$80,219K
Operating lease
right-of-use assets
-$33,086K
Depreciation and
amortization
$9,767K
Accelerated
amortization/impairment of right-of-use...
$6,156K
Accounts payable
$5,987K
Other assets
-$2,811K
Change in fair value of
investments, net
-$899K
Loss (gain) on
disposal of property and...
-$527K
Purchases of marketable
securities
$322,510K
Purchases of property and
equipment
$1,129K
Net cash used in
operating activities
-$394,736K
Canceled cashflow
$139,452K
Collaboration revenue
$67,671K
Interest income
$29,195K
Net loss
-$412,694K
Canceled cashflow
$96,866K
Operating lease
liabilities
-$54,951K
Deferred revenue
-$28,111K
Prepaid expenses and
other current assets
$26,352K
Accretion of investment
discounts and premiums
$5,858K
Accrued expenses
-$5,271K
Accounts receivable
$951K
Research and development
$388,861K
General and
administrative
$119,800K
Other (income)
expense, net
-$899K
Back
Back
Cash Flow
source: myfinsight.com
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA)